Abstract Cisplatin (cis-diammine-dichloro-platinum II) was initially discovered to prevent the
growth of Escherichia coli and was further recognized for its anti-neoplastic and cytotoxic …

Hodgkin lymphoma, a hematological malignancy of lymphoid origin that typically arises from
germinal-center B cells, has an excellent overall prognosis. However, the treatment of …

This report presents the recommendations of the WHO Expert Committee responsible for
updating the WHO Model Lists of Essential Medicines.. The goal of the meeting was to …

Summary Background Adolescents with Hodgkin lymphoma have worse disease outcomes
than children. Whether these differences persist within clinical trials is unknown. We …

Abstract Background In 2006, the Mexican government launched the Fund for Protection
Against Catastrophic Expenditures (FPGC) to support financially healthcare of high cost …

Background Early response to initial chemotherapy in Hodgkin lymphoma (HL) measured by
computed tomography (CT) and/or positron emission tomography (PET) after two to three …

Background Blood-based biomarker such as circulating tumor DNA (ctDNA) has emerged
as a promising tool for assessment of response to immunotherapy in solid tumors; But in …

Hodgkin lymphoma (HL) is a lymphoid malignancy that is typically derived from germinal-
center B cells. EBV infection, mutations in NF-κB pathway genes, and genetic susceptibility …

The National Clinical Trials Network lymphoid malignancies Clinical Trials Planning Meeting
(CTPM) occurred in November of 2014. The scope of the CTPM was to prioritize across the …

With the advent of targeted therapeutics in Langerhans cell histiocytosis (LCH), there is a
growing survivor population that might be at risk for late mortality from non-LCH causes …